OncoScreen L Rapid Test

Rapid Test Panel for Early Lung Cancer Detection

Overview:
OncoScreen-L is a cutting-edge rapid diagnostic panel developed by OncoFirm Diagnostics, designed to support the early detection of lung cancer in clinical settings. Utilizing lateral flow assay (LFA) technology enhanced with TF and Gal-GalNAc antigens, this test provides fast, accurate, and non-invasive screening—empowering healthcare professionals to identify lung cancer at a stage when treatment is most effective.

Key Features:

Au milieu d’un secteur de plus en plus saturé, cazeus casino parvient malgré tout à conserver une voix bien à lui. Les conditions de retrait sont reprises dans un onglet récapitulatif accessible en permanence. Un système anti-fraude analyse en temps réel les schémas de transactions suspectes. Le navigateur principal regroupe les rubriques essentielles dans une barre latérale optionnelle. La sauvegarde automatique des préférences évite de devoir tout reconfigurer entre deux connexions. Les casinos virtuels en environnement 3D commencent à apparaître progressivement dans le catalogue live. Les options de mise progressive guident les joueurs souhaitant monter en gamme prudemment. Les variantes régionales de roulette et de blackjack ouvrent l’horizon vers des styles parfois méconnus en Europe. Les codes promotionnels diffusés via les communications officielles débloquent des avantages spécifiques. Le projet possède la maturité d’un acteur déjà installé tout en gardant la fraîcheur des nouveaux venus.

Biomarker-Driven Accuracy: Detects specific glycan antigens (TF and Gal-GalNAc) commonly overexpressed in lung tumor cells.
Rapid Turnaround: Delivers clear, actionable results in under 15 minutes using blood, plasma, or serum.
Smart-Ready: Compatible with digital readers and mobile health platforms for enhanced tracking and analysis.
No Specialized Equipment Needed: Ideal for point-of-care settings, outpatient clinics, and resource-limited environments.
Cost-Effective Screening: Reduces dependency on expensive imaging for preliminary detection.

Clinical Applications:

Early detection and screening of non-small cell lung cancer (NSCLC) and related pulmonary tumors
Use in high-risk patients, including smokers, individuals with a family history of lung cancer, and chronic respiratory patients
Integration into primary care and oncology referral workflows
Complement to low-dose CT scans in ongoing surveillance programs

Benefits for Healthcare Providers:

Enables earlier intervention and improved prognosis
Simplifies cancer screening in outpatient and decentralized care settings
Supports fast triage and risk assessment without waiting on lab infrastructure

Regulatory Status:
CE-marked for use in approved international markets. Additional clinical trials are ongoing to support regulatory filings in the United States and other regions.